United Therapeutics Corporation | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Founded in 1996 by Martine Rothblatt, this biotechnology company develops treatments for pulmonary arterial hypertension (PAH), a severe lung disease. With co-headquarters in Silver Spring, Maryland, and Research Triangle Park, North Carolina, and additional facilities throughout the U.S. and Canada, it operates as a public benefit corporation committed to innovation, patient welfare, and environmental responsibility.

The core pharmaceutical portfolio centers around treprostinil, including major therapies such as Remodulin®, Tyvaso®, and Orenitram®. Alongside these, the company is pioneering organ manufacturing and transplantation technologies, notably in xenotransplantation using genetically modified animals. Its initiatives extend to advanced drug delivery systems and partnerships in hydrogen-powered organ delivery and AI-driven medical device software, with a strong emphasis on patient safety, medicine accessibility, and sustainable business practices.